Assistant Professor,School of Medical Science and Research Sharda University, Greater Noida, Uttar Pradesh.
Assistant Professor, School of Medical Science and Research Sharda University, Greater Noida, Uttar Pradesh; Corresponding Author.
J Assoc Physicians India. 2021 Jun;69(6):11-12.
In December 2019, SARS-COV-2 infection emerged in Wuhan, China causing COVID-19 and subsequently spread throughout the globe. A great uncertainty is associated with the disease progression, as the risk of severe COVID-19 is not uniform among all the patients. Systemic inflammation has been reported as a predictor for COVID-19 outcomes. Elevated levels of inflammatory markers are shown to be associated with endothelial dysfunction, cytokine storm and coagulopathy in COVID-19. There is a growing body of evidence, that these findings exert influence in the causation of mortality in patients with severe Covid-19. The present study is carried out with an aim to evaluate the clinical outcomes of patients by interrelating their clinical severity with inflammatory markers and CT (Computed tomography) severity score (CTSS).
The aim of the study is to correlate COVID-19 severity with inflammatory markers and CT severity score. We also aim to determine the optimal cut-off values for inflammatory markers and CT severity scores in order to establish their interrelationship to the disease severity.
It is a hospital-based retrospective observational study. The study was conducted over a period of four months (July 2020 to October 2020) based on data obtained from the records of patients, admitted with a laboratory confirmed SARS-COV-2 infection. The current study included a total of 84 patients, admitted to ICU with the severe COVID-19.Study tools included serum CRP, serum ferritin, D-dimer, neutrophil-to-lymphocyte ratio (NLR), interleukin-6 (IL-6) and 25-point CT severity score obtained from HRCT (high resolution computerized tomography) chest.
Out of 84 patients recruited, 54 patients were survivors and 30 patients were non-survivors (deceased). 78% of the study population was male and 22% was female. For survivors, average CTSS was 12.43 ± 5.7 and whereas average CTSS for non-survivors was 18.87 ± 4.68(p<0001). Average D-dimer was 2.5 ± 1.43 in the survivor group and 3.39 ± 0.95 for non-survivors (p<0.004). Correlation coefficient of CTSS with FiO2 is 0.685 (p<0.0001). The optimal cut-off value for predicting mortality for D-dimer is >2.4 (p<0.0012) and for CTSS is >15 (p<0.0001).
The disease severity was significantly correlated with CTSS and D- dimer. Severe COVID-19 was also associated with a high NLR (neutrophil to lymphocyte ratio) and moderately elevated inflammatory markers (CRP, Ferritin, IL-6). CTSS >15 and D-dimer >2.4 correlate strongly with mortality. CTSS has the greatest diagnostic accuracy for stratifying the disease severity and predicting the mortality among the markers/ characteristics compared.
2019 年 12 月,SARS-COV-2 病毒在中国武汉出现,引发了 COVID-19,并随后在全球范围内传播。由于 COVID-19 的疾病进展存在很大的不确定性,所有患者的严重 COVID-19 风险并不相同。已报道全身炎症是 COVID-19 结局的预测因子。研究表明,升高的炎症标志物水平与 COVID-19 中的内皮功能障碍、细胞因子风暴和凝血功能障碍有关。越来越多的证据表明,这些发现对严重 COVID-19 患者的死亡率产生影响。本研究旨在通过将患者的临床严重程度与炎症标志物和 CT(计算机断层扫描)严重程度评分(CTSS)相关联,评估患者的临床结局。
本研究旨在将 COVID-19 的严重程度与炎症标志物和 CT 严重程度评分相关联。我们还旨在确定炎症标志物和 CT 严重程度评分的最佳截断值,以确定它们与疾病严重程度的相互关系。
这是一项基于医院的回顾性观察性研究。该研究于 2020 年 7 月至 2020 年 10 月期间进行,基于从住院治疗 SARS-COV-2 感染的患者记录中获得的数据。本研究共纳入 84 名入住 ICU 的重症 COVID-19 患者。研究工具包括血清 CRP、血清铁蛋白、D-二聚体、中性粒细胞与淋巴细胞比值(NLR)、白细胞介素-6(IL-6)和 HRCT(高分辨率计算机断层扫描)胸部的 25 分 CT 严重程度评分。
在纳入的 84 名患者中,54 名患者存活,30 名患者死亡(死亡)。研究人群中 78%为男性,22%为女性。对于幸存者,平均 CTSS 为 12.43 ± 5.7,而非幸存者的平均 CTSS 为 18.87 ± 4.68(p<0001)。幸存者组的平均 D-二聚体为 2.5 ± 1.43,而非幸存者组为 3.39 ± 0.95(p<0.004)。CTSS 与 FiO2 的相关系数为 0.685(p<0.0001)。预测死亡率的 D-二聚体最佳截断值为 >2.4(p<0.0012),CTSS 为 >15(p<0.0001)。
疾病严重程度与 CTSS 和 D-二聚体显著相关。严重 COVID-19 还与高 NLR(中性粒细胞与淋巴细胞比值)和中度升高的炎症标志物(CRP、铁蛋白、IL-6)相关。CTSS >15 和 D-二聚体 >2.4 与死亡率密切相关。与其他标志物/特征相比,CTSS 对分层疾病严重程度和预测死亡率具有最高的诊断准确性。